Candida glabrata is the second leading cause of candidemia in U.S. hospitals. Current guidelines suggest that an echinocandin be used as the primary therapy for the treatment of C. glabrata disease due to the high rate of resistance to fluconazole. Recent case reports indicate that C. glabrata resistance to echinocandins may be increasing. We performed susceptibility testing on 1,380 isolates of C. glabrata collected between 2008 and 2013 from four U.S. cities, Atlanta, Baltimore, Knoxville, and Portland. Our analysis showed that 3.1%, 3.3%, and 3.6% of the isolates were resistant to anidulafungin, caspofungin, and micafungin, respectively. We screened 1,032 of these isolates, including all 77 that had either a resistant or intermediate MIC value with respect to at least one echinocandin, for mutations in the hot spot regions of FKS1 and FKS2, the major mechanism of echinocandin resistance. Fifty-one isolates were identified with hot spot mutations, 16 in FKS1 and 35 in FKS2. All of the isolates with an FKS mutation except one were resistant to at least one echinocandin by susceptibility testing. Of the isolates resistant to at least one echinocandin, 36% were also resistant to fluconazole. Echinocandin resistance among U.S. C. glabrata isolates is a concern, especially in light of the fact that one-third of those isolates may be multidrug resistant. Further monitoring of U.S. C. glabrata isolates for echinocandin resistance is warranted.
C andida species continue to be a leading cause of bloodstream infection in U.S. hospitals, especially in intensive care units (1, 2) . Although the antifungal armamentarium is limited, there are good options for the treatment of Candida species, especially with the arrival of the newest antifungal agents, the echinocandins (3, 4) . The echinocandins are intravenously administered agents with a favorable safety profile. As inhibitors of 1,3-␤-D glucan synthase in the cell wall, they have a mechanism of action different from that of the older azole antifungals, which act to disrupt ergosterol (cell membrane) synthesis. This alternate mechanism of action allows the echinocandins to be effective against Candida isolates that are azole resistant. Early studies of in vitro susceptibility showed resistance to echinocandins to be extremely low for all Candida species (5, 6) .
Candida glabrata has recently become the second-most-frequent cause of candidemia in the United States, surpassing C. parapsilosis and C. tropicalis (6) (7) (8) . While the ultimate cause for this increase in the prevalence of C. glabrata is unknown, the increase might be related to C. glabrata's higher incidence of resistance to fluconazole in comparison to most other Candida species (6) (7) (8) (9) . Because of the increased probability of fluconazole resistance, echinocandins are recommended as first-line therapy against C. glabrata (4) . Alarmingly, C. glabrata is the first species of Candida for which measurable resistance to echinocandins has been detected (6, 10) . Case reports of echinocandin-resistant C. glabrata following echinocandin therapy are becoming more common (11) (12) (13) (14) (15) (16) (17) . The majority of these resistant isolates have specific mutations in one of two "hot spot" regions of the FKS1 or FKS2 genes, which encode a subunit of the 1,3-␤-D glucan synthase protein, target of the echinocandins (11, (18) (19) (20) .
The Clinical and Laboratory Standards Institute (CLSI) developed species-specific MIC breakpoints for the echinocandins against C. glabrata (21) . These breakpoints were based upon phar-macokinetic/pharmacodynamic data, outcome data, MIC distribution, and the presence or absence of FKS mutations in the isolates (22) . One of the primary concerns when the breakpoints were set was that the breakpoint for resistance should encompass the MIC values for as many of the isolates with FKS mutations as possible, thus identifying all non-wild-type isolates. This consideration lowered the breakpoints for C. glabrata to 1 to 2 dilutions lower than those for C. albicans and C. tropicalis. The drawback when setting the breakpoints was the paucity of outcome data for patients with non-wild-type isolates. During the clinical trials of the echinocandins, though a great deal of outcome data were generated for patients with susceptible isolates, there were almost no patients with resistant (as defined after the fact) isolates.
A general theme that is becoming clear through ongoing susceptibility testing of C. glabrata and the echinocandins is that not all FKS mutations are created equal (23) (24) (25) (26) . While some mutations such as FKS2 S663P are associated with very high drug MIC values, others such as FKS2 F559Y are associated with much lower drug MIC values (24, 25) . In 2010, we published data on echinocandin resistance in population-based surveillance isolates from Atlanta, GA, and Baltimore, MD, prior to the official publication of the CLSI species-specific echinocandin breakpoint (24) . Here, we expand on that report with 5 years of surveillance data and the addition of two surveillance sites, the tricounty Portland, OR, metropolitan area and Knox County (Knoxville), TN, and surrounding counties. In this report, we identify many additional isolates with FKS mutations, compare the changes in MIC values caused by those mutations, and discuss the emergence of multidrug-resistant (MDR) C. glabrata.
MATERIALS AND METHODS
Case and isolate definitions. Isolates were obtained from individuals with an incident episode of candidemia (defined below) identified between 1 March 2008 and 9 June 2013 for residents of metropolitan Atlanta, GA, between 1 June 2008 and 9 June 2013 for residents of Baltimore City or Baltimore County, MD, between 1 January 2011 and 9 June 2013 for residents of Knoxville (Knox County), TN, and surrounding counties, and between 1 January 2011 and 9 June 2013 for residents of the tricounty metropolitan area that includes Portland, OR. When available, isolates from non-catchment-area residents hospitalized in the catchment area were included. An incident episode was defined as in previous reports (6, 27) . Institutional review board (IRB) approval or a waiver was obtained for all participating institutions.
Isolate storage and DNA extraction. All isolates were initially stored in glycerol at Ϫ70°C. Isolates were identified using a Luminex assay or DNA sequencing of the D1/D2 subunit of the 28S ribosomal DNA (rDNA) at the CDC as previously described (28) . DNA was extracted using a MoBio microbial DNA isolation kit (Mo Bio Laboratories, Inc., Carlsbad, CA) according to the manufacturer's instructions.
Antifungal susceptibility testing. Antifungal susceptibility testing was performed with broth microdilution with anidulafungin, caspofungin, and micafungin as described in the Clinical and Laboratory Standards Institute (CLSI) M27-A3 document guidelines (42) using frozen RPMI microbroth trays custom manufactured with no indicator dye (Trek Diagnostics, Cleveland, OH). Results were read visually after 24 h, and the MIC was identified as the lowest concentration of drug that caused a significant decrease in growth compared to the control well results. Recently published CLSI M27-S4 (21) breakpoints were used. Isolates of C. glabrata with a drug MIC of 0.25 g/ml were considered intermediate to caspofungin and anidulafungin, while those with a drug MIC of 0.12 g/ml were considered intermediate to micafungin. Isolates of C. glabrata with a drug MIC of Ն0.5 g/ml were considered resistant to caspofungin and anidulafungin, while those with a drug MIC of Ն0.25 g/ml were considered resistant to micafungin. For fluconazole, a MIC of Ն64 g/ml was considered to represent resistance.
PCR amplification and sequencing. Amplification of FKS1 and FKS2 HS1 and HS2 has been described previously (24) . Hotspot mutations were detected using either a newly developed Luminex assay (29) or sequencing. Susceptible isolates were screened only for mutations in FKS1 HS1 and FKS2 HS1. All isolates with at least one drug MIC value in the intermediate or resistant range were sequenced at all four hot spot regions. Sequencing of the PCR products was performed using a BigDye Terminator kit (Applied Biosystems, Foster City, CA). Sequences were analyzed using Sequencher 5.1 software (Gene Codes Corporation, Ann Arbor, MI).
RESULTS
A total of 1,380 C. glabrata bloodstream isolates (679 from GA, 580 from MD, 89 from TN, and 32 from OR) were collected between 2008 and 2013 (Table 1) . Although the proportion remained relatively constant, the number of C. glabrata isolates collected yearly decreased over the study period, as did the overall number of Candida isolates. Susceptibility testing of anidulafungin, caspofungin, and micafungin was performed on all isolates. The majority of isolates were susceptible to all three echinocandins, but a substantial minority was in the intermediate (n ϭ 19, 1.4%) or resistant (n ϭ 58, 4.2%) range for at least one echinocandin ( Table 2 ). The distribution of the 58 resistant isolates was reasonably consistent across the three echinocandins, with 43 (3.1%), 45 (3.3%), and 50 (3.6%) isolates being resistant to anidulafungin, caspofungin, and micafungin, respectively. Identification of mutations in FKS genes. A total of 1,032 isolates were screened for mutations in FKS1 HS1 and FKS2 HS1: 77 isolates that had drug MIC values in the intermediate or resistant range (Table 3 ) and 955 isolates with drug MIC values in the susceptible range. In addition, all 77 isolates with drug MIC values in the intermediate or resistant range were screened for mutations in FKS1 HS2 and FKS2 HS2.
Fifteen isolates had mutations in FKS1 HS1: five unique mutations were detected, including 7 isolates with an S629P mutation, 6 isolates with an R631G mutation, 1 isolate with a D632V mutation, 1 isolate with a D632Y mutation, and 1 isolate with a mutation just outside the hot spot region at I634V. No mutations were detected in FKS1 HS2.
Thirty-five isolates had mutations in FKS2 HS1: seven unique mutations were detected, including 21 isolates with an S663P mutation, 5 isolates with an F659Y mutation, 3 isolates with D666V mutation, 2 isolates with an S663F mutation, 1 isolate with an F659S mutation, 1 isolate with a P667H mutation, and 2 isolates with a deletion at F658. All three of the isolates with the D666V mutation were found in conjunction with a mutation in FKS1, two with S629P and one with R631G.
No mutations were detected in FKS2 HS2. There was only a single isolate with an FKS mutation (FKS1, D632Y) for which none of the three echinocandins gave an MIC value in the resistant range, although the value for anidulafungin was in the intermediate range.
Using an FKS mutation as a marker of resistance, micafungin MIC values were the strongest predictor of isolates possessing mutations; 43/47 (91%) isolates with an FKS mutation had an MIC value in the resistant range. Anidulafungin (85% of isolates with an FKS mutation in the resistant range) and caspofungin (81% of isolates with an FKS mutation in the resistant range) MIC values were slightly less predictive of resistance due to an FKS mutation. Though there were six isolates with micafungin MIC values in the resistant range that did not have an FKS mutation and six isolates with caspofungin MIC values in the resistant range that did not have an FKS mutation, there were only two isolates with anidulafungin MIC values in the resistant range that did not have an FKS mutation. Two isolates with FKS mutations were identified as solely resistant to anidulafungin, and five isolates with FKS mutations (four with the mutations in FKS1 and one with the mutations in both FKS1 and FKS2) were identified as solely resistant to micafungin. Only one isolate resistant to all three echinocandins did not have an FKS mutation. Overall, 81% of isolates showing resistance to at least one echinocandin had an FKS mutation.
Detection of multidrug resistance. Because fluconazole is still frequently used to treat some C. glabrata infections, we also screened the entire collection of isolates for resistance to fluconazole (MIC Ն 64 g/ml). Of the 1,380 isolates, 142 (10.3%) were resistant to fluconazole. Of the fluconazole-resistant isolates, 21 (14.8%) were also resistant to at least one echinocandin (Table 3) .
Conversely, 36.2% of the isolates that were resistant to an echinocandin were also resistant to fluconazole.
Treatment and outcome. Antifungal treatment and 30-day mortality data were available for 804 patients with C. glabrata candidemia. All-cause mortality for these patients was 42%. For those patients who were treated with an echinocandin only (n ϭ 169), the all-cause mortality was slightly lower at 40%. For patients who did not receive any echinocandin as part of their therapy (n ϭ 232), the all-cause mortality was 49%. The all-cause mortality for patients who received an echinocandin either exclusively or in addition to other antifungal therapy was lower at 33%. The difference in 30-day outcomes between those patients with a C. glabrata isolate who received an echinocandin either exclusively or in addition to other antifungal therapy and those who received no echinocandin was statistically significant (Fisher's exact test, P Ͻ 0.001). The presence of an FKS mutation did not appear to affect patient survival; 22 (76%) patients with C. glabrata isolates with FKS mutations survived, and seven (24%) patients died within 30 days of the initial culture. Three of the seven who died were treated with an echinocandin only. Six of the 22 patients who survived their infections were treated with an echinocandin only, including two patients infected with isolates harboring the FKS2 S663P mutation and anidulafungin, caspofungin, and micafungin MIC values of 2.0, 2.0, and 0.5 g/ml and of 2.0, 16, and 1.0 g/ml, respectively. The remaining patients who survived C. glabrata candidemia and had an isolate with an FKS mutation were treated either with something other than an echinocandin (7 patients) or with an echinocandin and another antifungal.
DISCUSSION
With the clinical implementation of echinocandins in the decade beginning in 2000, the general belief was that resistance to this antifungal class would be rare. For the most part, that has been the case, with the overall susceptibility of all Candida isolates at around 99% (6, 8, 30) . While occasional case reports of echinocandin resistance were published, these were initially infrequent.
In the United States, the rate of resistance of C. glabrata to the echinocandins had started to increase into the 2% to 3% range by 2010 (10, 24, 30) . Even more alarming, resistance to echinocandins was higher among C. glabrata isolates already resistant to fluconazole (23) . This trend was cause for alarm and is an indication that there needs to be closer scrutiny of echinocandin resistance in C. glabrata in the United States. To that end, we screened almost 1,100 C. glabrata isolates for drug MIC values in the resistant range and for FKS mutations that may be causing resistance. Several important findings have come from this study. The first is that, despite the fact that the number of C. glabrata candidemia cases at our study sites has decreased, the level of echinocandin resistance has remained steady or has increased. The second is that elevated MIC values and echinocandin resistance are caused by an increasing number of distinct mutations in C. glabrata, primarily in the FKS1 and FKS2 genes. The third and final significant finding is that multidrug resistance (MDR) among C. glabrata isolates was high (1.5%) in our catchment area and may be an indication of future problems with MDR C. glabrata.
We used our surveillance data set to measure the proportion of C. glabrata isolates resistant to echinocandins over the course of our surveillance. For this exercise, we used all isolates received at hospitals in the catchment areas, not just isolates from patients residing in the catchment area. While this does not allow us to generate a population-based rate of resistance, it does provide a surveillance profile of resistance detected in the catchment area hospitals. In the hospitals in Atlanta, GA, echinocandin resistance in C. glabrata increased between 2008 and 2013 (Table 1) . While it dropped considerably between 2009 and 2010, it steadily rose after 2010 to a proportion of over 10% in 2013, even though the number of isolates received in 2013 dropped sharply. Although there was a single large hospital with 30% of the resistant isolates, resistant isolates were recovered from 11 different hospitals in Atlanta. Similarly, in Baltimore, MD, echinocandin resistance in C. glabrata peaked at 9.7% in 2011, fell to 5% in 2012, and remained steady at 6% in 2013 despite a fairly sharp drop in the number of isolates received. Two large hospitals accounted for 62% of the resistant isolates, but resistant isolates were recovered from nine different hospitals in Baltimore. Despite having fewer than 100 isolates over 3 years of surveillance, the proportion of echinocandin resistance in C. glabrata isolates from Knoxville, TN, was 3.4%. No echinocandin-resistant C. glabrata isolates were received from Oregon among the 32 isolates received over 3 years. These results are similar to those of a single-institution study where the proportion of C. glabrata remained steady but echinocandin resistance rose steadily over the 10-year period between 2001 and 2010 (26) .
Among 47 isolates with FKS mutations, 12 unique mutations were identified: five in FKS1 and seven in FKS2. All of these mutations were in HS1; we did not detect any HS2 mutations. Among the limitations of this study were that we did not search for FKS mutations outside the HS region and that we did not look for HS2 mutations among any isolates that were not intermediate or resistant to at least one echinocandin. Nevertheless, FKS mutations were detected in 81% of the echinocandin-resistant isolates. In a recent study by Alexander and coworkers (26) , of the 25 patient isolates with FKS mutations, only two of the mutations were in HS2 (both I1379V); both isolates had drug MICs in the susceptible range, and both patients were treated with an echinocandin and recovered. Similarly, Castanheira and coworkers (25) identified 29 isolates with FKS mutations, and only one had an HS2 mutation. This isolate (with a P1371S mutation) was susceptible to micafungin and anidulafungin but had an intermediate caspofungin MIC. It is reasonable to conclude that the majority of mutations that affect C. glabrata susceptibility to the echinocandins would be in the FKS1 and FKS2 HS1 regions, which should be the primary targets of future assays developed to detect resistance (29) .
It is clear from the MIC data that not all FKS mutations cause the same level of resistance. Within FKS1, mutations at S629 result in higher drug MIC values than mutations at R631 or D632. Mutations at R631 in most cases were reflected by higher micafungin MICs but lower caspofungin and anidulafungin MICs (in the susceptible to intermediate range). The mutation D632V had resistant drug MIC values for all three echinocandins, but the mutation D632Y did not have resistant drug MIC values for any of the echinocandins. S629P was similar to S663P in that it was associated with drug MIC values at either the low end or high end of the resistant category (23, 24) . For equivalent mutations (FKS1 S629P is functionally equivalent to FKS2 S663P), the mutation in the FKS2 gene was always associated with higher drug MIC values than the mutation in the FKS1 gene. It is interesting that in our collection, with the exception of S629P and S663P, FKS1 and FKS2 equivalents were not seen. There were no FKS2 equivalents for FKS1 R631 mutations, and there were no FKS1 equivalents for FKS2 F659 mutations, even though both of these mutations have been noted in other studies (25, 26) .
As has been reported previously (23, 26) , in our study, resistance of C. glabrata to fluconazole increased the likelihood that the isolate would be resistant to an echinocandin and vice versa. Candida glabrata is capable of genomic changes, including point mutations as well as changes in chromosome structure that may be mechanisms of adaptation to changing environments (31, 32) . These genomic changes may be a coping mechanism that allows it to rapidly become resistant to multiple drugs following limited exposure (13, 17, (33) (34) (35) . For MDR C. glabrata with resistance to azoles and echinocandins, the only remaining available antifungal is amphotericin B. This is especially alarming because Candida glabrata carriage and infections increase as patients age (27, (36) (37) (38) (39) and because amphotericin B is often poorly tolerated in the elderly.
Prior echinocandin use has been shown to be a risk factor for failure of echinocandin therapy in C. glabrata (12, 16, 40) . However, there is evidence that some patients with isolates that show in vitro echinocandin resistance, even those harboring FKS mutations, do respond to echinocandin therapy (15, 26) . Additionally, there is evidence from mouse infection models that there may be differential effects of the echinocandins depending on which FKS mutation is present (41) . This is an indication that, as we see with other infections, the attributes of the infecting organism are not the sole determining factor for the successful completion of therapy. In our study, we had three patients who were infected with C. glabrata isolates that harbored FKS mutations (including two with the S663P mutation) but survived even though their sole antifungal therapy was an echinocandin. It is also important that the all-cause 30-day mortality of our patients was considerably lower when an echinocandin was used in a patient. We did not collect information on whether the echinocandin was used as therapy or for prophylaxis, only that the patient had received at least one dose of an echinocandin. It should also be noted that isolates received as part of surveillance were the incident isolates and additional isolates were not collected; it is not known if any of the isolates went on to develop echinocandin resistance following exposure.
Clearly, there is further work to be done to further our understanding of echinocandin use for the treatment of C. glabrata. There is a need for more dosage, duration, and outcome data, especially among patients harboring isolates with FKS mutations. The echinocandin breakpoints for C. glabrata were developed largely on the basis of differentiation between isolates with and without FKS mutations (22) . Our data indicate that these breakpoints perform that function reasonably well. With limited options for treatment, it is important to determine whether echinocandins can be used for isolates that harbor FKS mutations but have drug MIC values at the lower end of the resistance range. With current advances in molecular detection and characterization of infecting species, direct assessment of FKS mutations should become part of the routine identification protocols for C. glabrata isolates in the clinical laboratory. Where it is practical, laboratories should consider routine MIC testing of C. glabrata isolates collected from sterile sites. Continued collection of C. glabrata and echinocandin treatment outcomes will allow moreinformed determinations of the value of these drugs in the antifungal armamentarium.
